Business

July 25, 2014

RTP pharma company receives FDA fast-track status

The Food and Drug Administration has given fast-track status to a treatment called HumaGraft being developed by Humacyte, a Research Triangle Park pharmaceutical company.

Related content

Comments

Videos

Editor's Choice Videos